Idera, MD Anderson Cancer Center to enhance development of intratumoral TLR9 agonist
IMO-2125 is a TLR9 agonist that was assessed subcutaneously in around 80 human subjects. It was well tolerated and demonstrated to induce immune responses. Idera Pharmaceuticals CEO Vincent
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.